Endocrine Abstracts

Background: Starvation ketoacidosis (SKA) represents one of three metabolic acidosis caused by the accumulation of ketone bodies in blood. While easily treated, it is a diagnosis that can be easily mimic diabetic ketoacidosis, particularly in the presence of hyperglycemia1.Case: We report a 54-year old female, who had been feeling unwell with ongoing nausea and vomiting, and not eating nor drinking for 5 days. She had a history of alcohol exce...

Loss-of-function mutations of the calcium-sensing receptor (CaSR), a G-protein-coupled receptor (GPCR), result in familial hypocalciuric hypercalcaemia (FHH), a disorder of extracellular calcium homeostasis affecting the parathyroids and kidneys. However, around 35% of FHH patients do not have CaSR mutations. A form of FHH, designated FHH2, has been mapped to chromosome 19p. The GNA11 gene, encoding G-protein α11 (Gα11), a component of the CaSR sign...

Background: Capecitabine and temozolomide (CAPTEM) is a common regimen for the treatment of metastatic, well-differentiated pancreatic neuroendocrine tumors (PNETs). However, it is unknown whether certain genomic profiles predict response to CAPTEM. PNETs often contain mutations in MEN1, ATRX, DAXX, and the PI3K/AKT/mTOR pathway. We sought to determine whether the mutational status of these genes may correlate with progression-free survival (PFS) on CAPTEM.<p clas...

Journal of Endocrinology, 2019, 245(1): 39–51 (DOI: https://doi.org/10.1530/JOE-19-0413)...

Background: Treatment options are limited in patients with metastatic neuroendocrine neoplasms (NEN). Combination temozolomide and nivolumab showed encouraging objective response rates of 35.7% in advanced NEN regardless of site of origin, with response rates of 64% in lung NEN and 67% in pancreatic NEN (NCT03728361). We present updated survival data on follow-up from a phase II trial of combination nivolumab and temozolomide in patients with advanced NEN.<p class="abstext...